文献速递神经肿瘤

12种罕见中枢神经系统肿瘤的流行病学与生存分析:CBTRUS与NCI-CONNECT联合报告

Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.
PubMed 文献 · J Neurooncol · 2019-06-17

该研究利用美国CBTRUS 2000–2014年数据及SEER数据,计算12种成人罕见脑及中枢神经系统肿瘤的年龄调整发病率、患病率和相对生存率。12种罕见组织学合计AAIR为1.47/10万,少突胶质细胞瘤发病率最高(AAIR=0.40/10万);室管膜瘤患病率最高(4.11/10万),胶质肉瘤相对生存率最低。

要点

  • 12种罕见CNS肿瘤合计AAIR为1.47/10万,少突胶质细胞瘤发病率最高。
  • 室管膜瘤患病率最高(4.11/10万),少突胶质细胞瘤次之(3.68/10万)。
  • 合计1年、5年、10年相对生存率分别为82.3%、64.0%、55.4%;胶质肉瘤最低。

核心结论

  • 12种罕见脑及CNS肿瘤的组织学特异性发病率、患病率和生存数据此前未见报告,本研究提供了统计基础。
  • 这些数据可用于理解此类肿瘤的疾病负担,并为前瞻性临床试验设计提供疾病特异性依据。

研究设计与样本

  • 基于CBTRUS 2000–2014年数据计算12种罕见组织学的平均年年龄调整发病率(AAIR),按性别、种族、族裔和年龄分层。
  • 利用NCI的SEER数据计算相对生存(RS)估计。
  • 使用CBTRUS的年年龄特异性发病率和SEER的生存数据估算2014年时点患病率。

主要发现

  • 12种罕见组织学合计总体AAIR为1.47/10万,组织学特异性发病率最高为少突胶质细胞瘤(AAIR=0.40/10万)。
  • 多数组织学在男性、成人(40岁及以上)、白人和非西班牙裔人群中更常见。
  • 室管膜瘤患病率最高,为4.11/10万;少突胶质细胞瘤次之,为3.68/10万。
  • 12种肿瘤合计1年、5年、10年相对生存率分别为82.3%、64.0%、55.4%。
  • 室管膜瘤相对生存率最高(1年=94.2%,5年=83.9%,10年=78.6%),胶质肉瘤最低(1年=42.5%,5年=5.6%,10年=2.9%)。

关键数值与推荐

  • 总体AAIR:1.47/10万(12种罕见组织学合计)。
  • 组织学特异性最高AAIR:少突胶质细胞瘤0.40/10万。
  • 患病率:室管膜瘤4.11/10万,少突胶质细胞瘤3.68/10万。
  • 合计相对生存率:1年82.3%,5年64.0%,10年55.4%。
  • 室管膜瘤RS:1年94.2%,5年83.9%,10年78.6%;胶质肉瘤RS:1年42.5%,5年5.6%,10年2.9%。

临床怎么用

  • 可为神经肿瘤临床医生提供12种罕见CNS肿瘤的发病率、患病率和生存率的基线参考。
  • 有助于识别高疾病负担或预后极差的罕见组织学(如胶质肉瘤),指导临床咨询与随访强度。
  • 为设计针对罕见CNS肿瘤的前瞻性临床试验提供疾病特异性统计依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Population-based cancer statistics, including histology-specific incidence, prevalence, and survival are essential to evaluating the total burden due to disease in a population. The National Cancer Institute's (NCI) Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) was developed to better understand tumor biology and patient outcomes for 12 selected brain and other central nervous system (CNS) tumor histologies that are rare in adults to improve approaches to care and treatment. The aim of this study was to determine the incidence, prevalence, and survival of these selected rare histologies. METHODS: Data from the Central Brain Tumor Registry of the United States (CBTRUS) from 2000 to 2014 were used to calculate average annual age-adjusted incidence rates (AAIR) per 100,000 population overall and by sex, race, ethnicity, and age. NCI's Surveillance, Epidemiology and End Results (SEER) data were used to calculate relative survival (RS) estimates. Point prevalence for 2014 was estimated using annual age-specific incidence and survival from CBTRUS and SEER, respectively. RESULTS: Overall AAIR was 1.47 per 100,000 for all 12 rare histologies combined, with the highest histology-specific incidence in oligodendrogliomas (AAIR = 0.40/100,000). Overall, most histologies were more common in males, adults (age 40 + ), Whites, and non-Hispanics. Ependymomas were the most prevalent histology at 4.11 per 100,000; followed by oligodendrogliomas at 3.68 per 100,000. Relative survival at 1-, 5-, and 10-years was 82.3%, 64.0%, and 55.4%, respectively for all 12 selected brain and other CNS tumor types combined. Ependymomas had the highest RS (1-year = 94.2%, 5-year = 83.9%, 10-year = 78.6%) and gliosarcomas had the lowest relative survival rate (1-year = 42.5%, 5-year = 5.6%, 10-year = 2.9%) at all three time points. CONCLUSIONS: Incidence and prevalence of these rare brain and other CNS tumor histologies have not been previously reported. Along with survival, these data provide a statistical foundation to understand the impact of these cancers and provide important disease-specific data for the design of prospective clinical trials.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Truitt G, Gittleman H, Leece R, et al. Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. J Neurooncol. 2019. PMID: 31209773. doi:10.1007/s11060-019-03215-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。